Our Technology
Disruptive Breakthrough in Cancer Technology
The development of our patented filter marks a significant advancement in manufacturing process technology. Creating over 100 million pores with the precise geometry and inter-beading required cannot be achieved through standard manufacturing techniques, and the processes for quality assurance are proprietary to Onco Filtration.
The Onco Filter represents a versatile cancer technology with broad-spectrum applicability. Solid tumor CTCs share common physical and mechanical traits, allowing the filter to effectively target virtually all solid tumor types and subtypes, regardless of their specific characteristics.
-
Current CTC filtering technologies generally process less than 10 milliliters
-
About a dozen technologies exist to remove CTCs from whole blood
-
These technologies are well published in competitive analyses in the Journal of Hematology and Oncology
The Data
The Onco Filter successfully filtered multiple solid tumor lines out of whole blood. We manufactured thirty-six Onco Filters over two manufacturing runs in the fourth quarter of 2021 with 100% success where 36 of 36 Onco Filters cleared quality control. In the first quarter of 2022, we successfully ran whole blood through and captured multiple lines of tumor cells with the Onco Filters that we manufactured in the fourth quarter 2021.
Since 2022, we have been exploring multiple applications for our proprietary and patented filter technology.
